Evidence map›Paper›PMID 41743232›Full record

ReviewInternational journal of nanomedicine2026

Nanotechnology-Driven Precision Modulation of Transplant Immunity: From Mechanistic Insights to Clinical Tolerance.

Long Zhang, Kunzhe Wu, Shuhan Si, Xiaoyu Zhang, Feiran Jia, Xiaohua Xu, Xuefei Jin

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Long Zhang *Department of Urology, Second Ward, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China.ORCID 0009-0006-1731-7241
Kunzhe Wu *Department of Urology, Second Ward, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China.
Shuhan SiDepartment of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China.
Xiaoyu ZhangDepartment of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China.
Feiran JiaDepartment of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China.
Xiaohua XuDepartment of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China.
Xuefei JinDepartment of Urology, Second Ward, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organ transplantation represents a definitive therapeutic modality for end-stage organ failure, yet it is plagued by formidable challenges encompassing allogeneic immune rejection and the inherent limitations of conventional immunosuppressive regimens. Nonspecific immunosuppression not only precipitates severe adverse events such as opportunistic infections and malignancies but also fails to precisely modulate the local immune microenvironment. The core innovation of this review lies in the systematic integration of the distinctive advantages of nanotechnology-including targeted delivery, multifunctional synergy, and stimuli-responsive intelligence-with transplant immune regulation, encompassing a comprehensive analysis spanning mechanistic elucidation, strategic optimization, and clinical translation. We first delineate the pivotal mechanisms underlying immune rejection, including the regulatory roles of the transplant immune microenvironment, T lymphocytes, macrophages, and oxidative stress in ischemia-reperfusion injury (IRI). Subsequently, we conduct a critical comparison between conventional immunosuppressants and emerging therapeutic strategies, with a particular focus on how nanoplatforms enable spatiotemporally precise immune modulation. This includes targeting the transplant immune microenvironment, reprogramming T cell/macrophage functions, mitigating oxidative stress, facilitating tissue repair and regeneration, as well as inducing immune tolerance via both active and passive approaches. Additionally, we discuss innovative nanotechnological strategies such as the optimization of organ cryopreservation protocols. In summary, nanotechnology offers a targeted, multifunctional, and long-acting paradigm for transplant immune regulation, albeit confronted with formidable translational bottlenecks. Future integration with interdisciplinary technologies will undoubtedly propel the field toward the goal of precision immune modulation in organ transplantation.

Indexed as

immune rejectionimmune toleranceimmunosuppressionnanodrug deliverynanotechnologytransplant immunity

Identifiers

PMID41743232
PMCPMC12929948

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.